Protective aminoacid agents for use in peritoneal dialysis
Intraperitoneal administration of L-glutamine derivatives addresses liver disease and ESKD induced by peritoneal dialysis, effectively protecting the liver and mitigating kidney damage.
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- ZYTOPROTEC FLEXIBLE KAPITALGESELLSCHAFT
- Filing Date
- 2026-04-17
- Publication Date
- 2026-07-10
AI Technical Summary
Existing peritoneal dialysis treatments often induce liver disease and end-stage kidney disease (ESKD) due to liver dysfunction, necessitating a protective agent to prevent or treat these conditions.
The use of L-glutamine, L-alanyl-L-glutamine, L-glutaminyl-L-alanine, L-glutaminyl-L-glycine, or mixtures thereof, administered via intraperitoneal administration, to protect the liver during peritoneal dialysis.
These amino acid agents effectively prevent and treat liver disease and ESKD associated with peritoneal dialysis, providing liver protection and improving patient outcomes.
Smart Images
Figure 00000000_0003_ABST 
Figure 00000000_0000_ABST 
Figure 00000000_0001_ABST 
Figure 00000000_0002_ABST
Abstract
Description
This invention relates to a protective amino acid agent for peritoneal dialysis, selected from the group consisting of L-glutamine, L-alanyl-L-glutamine, L-glutyl-L-alanine, L-glutyl-L-glycine, L-glycyl-L-glutamine, or mixtures thereof, specifically for the prevention and / or treatment during peritoneal dialysis treatment of: (A) liver disease induced by said peritoneal dialysis treatment and / or (B) liver dysfunction mediated by said peritoneal dialysis treatment associated with end-stage renal disease (ESKD), wherein said protective agent is administered via intraperitoneal administration. Abstract PROTECTIVE AMINOACID AGENTS FOR USE IN PERITONEAL DIALYSIS The present invention relates to a protective agent selected from the group consisting of L-glutamine, L-alanyl-L-glutamine, L-glutaminyl-L-alanine, L-glutaminyl-L-glycine, L-glycinyl-L-glutamine or mixtures thereof, for the specific use in the prevention and / or treatment, in the course of a peritoneal dialysis treatment, of (A) liver diseases induced by said peritoneal dialysis treatment and / or (B) diseases associated with end-stage kidney disease (ESKD) mediated by liver dysfunction induced by said peritoneal dialysis treatment, whereby said protective agent is administered by intraperitoneal administration. Abstract
Claims
Claims1. A protective agent selected from the group consisting of L-glutamine, L-alanyl-L- glutamine, L-glutaminyl-L-alanine, L-glutaminyl-L-glycine, L-glycinyl-L-glutamine or mixtures thereof, for the specific use in the prevention and / or treatment, in the course of a peritoneal dialysis treatment, of(A) liver diseases induced by said peritoneal dialysis treatment and / or(B) diseases associated with end-stage kidney disease (ESKD) mediated by liver dysfunction induced by said peritoneal dialysis treatment, whereby said protective agent is administered by intraperitoneal administration.
2. Protective Agent for use according to claim 1, wherein the liver diseases induced by said peritoneal dialysis treatment (A) are chronic liver diseases, especially non-infectious liver inflammation.
3. Protective Agent for use according to claim 2, wherein said non-infectious liver inflammation includes non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and metabolic (dysfunction)-associated fatty liver disease (MAFLD).
4. Protective Agent for use according to any one of the preceding claims, wherein said ESKD-associated diseases mediated by liver dysfunction (B) are cardiovascular diseases, especially artherosclerotic cardiovascular diseases, including inflammation driven cardiovascular diseases and metaflammation driven cardiovascular diseases.
5. Protective Agent for use according to any one of the preceding claims, wherein administration of the protective agent starts from the outset of said peritoneal dialysis treatment.
6. Protective Agent for use according to any one of claims 1 to 4, wherein administration of the protective agent starts after a period from the outset of said peritoneal dialysis treatment.
7. Protective Agent for use according to claim 6, wherein administration of the protective agent starts once indicators for liver disease or liver-mediated system inflammation, especially metaflammation, or cardiovascular disease, are detected.
8. Protective Agent for use according to claim 7, wherein said indicators are selected from the group consisting of biomarkers, such as laboratory markers, and / or imaging findings.
9. Protective agent for use according to any of the preceding claims, whereby the protective agent is administered as a component of a peritoneal dialysis fluid (PDF).
10. Protective agent for use according to claim 9 wherein the fluid is administered as the only PDF in the course of the PD treatment.
11. Protective agent for use according to claim 9, wherein the fluid is administered in combination with another peritoneal dialysis fluid.
12. Protective agent for use according to any one of claims 9 to 11, wherein the fluid is based on glucose as the osmotic agent.
13. Protective agent for use according to any one of the preceding claims, wherein the protective agent is L-alanyl-L-glutamine, optionally in mixture with one or more of the other protective agents.